



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/800,350	
			Filing Date	March 12, 2004	
			First Named Inventor	Valery Krasnoperov	
			Art Unit	1642	
			Examiner Name	S. E. Aeder	
Sheet	1	of	1	Attorney Docket Number	VASG-P01-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
/SA/	BA	WO 04/080425	09-23-2004	Vasgene Therapeutics, Inc.		
	BB	WO 04/024773	03-25-2004	The Queen Elizabeth Hospital		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Berclaz Gilles et al., "Loss of EphB4 receptor tyrosine kinase protein expression during carcinogenesis of the human breast," <u>Oncology Reports</u> , 9(5):985-989 (2002).	
	CB	Caplen, N.J., "RNAi as a Gene Therapy Approach," <u>Expert Opin. on Biol. Therapy</u> , 3(4):575-586 (2003).	
	CC	Cromer et al., "Identification of genes associated with tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis," <u>Oncogene</u> , Basingstoke, Hants, GB, 23(14):2484-2498 (2004).	
	CD	Santa Cruz, "EphB4 (N-19): sc-7285," <u>Product Catalog of Santa Cruz Biotechnology</u> (1999).	
	CE	Sinha et al., "Expression of EphB4 in head and neck squamous cell carcinoma," <u>Bar, Nose, and Throat Journal</u> , 82(11):866, 869-870, 887 (2003).	
	CF	Takai et al., "Expression of receptor tyrosine kinase EphB4 and its ligand Ephrin-B2 is associated with malignant potential in endometrial cancer," <u>Oncology Reports</u> , National Hellenic Research Foundation, 8(3):567-573 (2001).	
	CG	Yang et al., "Gene Targets of Antisense Therapies in Breast Cancer," <u>Expert Opin. on Therapeutic Targets</u> , 6(3):375-385 (2002).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Sean Aeder/	Date Considered	10/14/10
-----------------------	--------------	--------------------	----------